Ifinatamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Neuroendocrine Tumors.
IDWeek 2024: strategic approaches and challenges in mpox vaccination – Pharmaceutical Technology
At IDWeek 2024 in Los Angeles, California, recent updates on mpox (formerly known as monkeypox) were discussed. Significant advancements and remaining hurdles in vaccination strategies